Literature DB >> 10607834

Mutations affecting mRNA splicing are the most common molecular defects in patients with neurofibromatosis type 1.

E Ars1, E Serra, J García, H Kruyer, A Gaona, C Lázaro, X Estivill.   

Abstract

Neurofibromatosis type 1 (NF1) is one of the most common inherited disorders in humans and is caused by mutations in the NF1 gene. To date, the majority of the reported NF1 mutations are predicted to result in protein truncation, but very few studies have correlated the causative NF1 mutation with its effect at the mRNA level. We have applied a whole NF1 cDNA screening methodology to the study of 80 unrelated NF1 patients and have identified 44 different mutations, 32 being novel, in 52 of these patients. Mutations were detected in 87% of the familial cases, but in 51% of the sporadic ones. At least 15 of the 80 NF1 patients (19%) had recurrent mutations. The study shows that in 50% of the patients in whom the mutations were identified, these resulted in splicing alterations. Most of the splicing mutations did not involve the conserved AG/GT dinucleotides of the splice sites. One frameshift, two nonsense and two missense mutations were also responsible for alterations in mRNA splicing. The location and type of mutation within the NF1 gene, and its putative effect at the protein level, do not indicate any relationship to any specific clinical feature of NF1. The high proportion of aberrant spliced transcripts detected in NF1 patients stresses the importance of studying mutations at both the genomic and RNA level. It is possible that part of the clinical variability in NF1 could be due to mutations affecting mRNA splicing, which is the most common molecular defect in NF1.

Entities:  

Mesh:

Year:  2000        PMID: 10607834     DOI: 10.1093/hmg/9.2.237

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  102 in total

1.  Distribution and characterization of regulatory elements in the human genome.

Authors:  Jacek Majewski; Jurg Ott
Journal:  Genome Res       Date:  2002-12       Impact factor: 9.043

2.  Missense mutations in hMLH1 and hMSH2 are associated with exonic splicing enhancers.

Authors:  Ivan P Gorlov; Olga Y Gorlova; Marsha L Frazier; Christopher I Amos
Journal:  Am J Hum Genet       Date:  2003-10-01       Impact factor: 11.025

3.  A novel long-range PCR sequencing method for genetic analysis of the entire PKD1 gene.

Authors:  Ying-Cai Tan; Alber Michaeel; Jon Blumenfeld; Stephanie Donahue; Tom Parker; Daniel Levine; Hanna Rennert
Journal:  J Mol Diagn       Date:  2012-05-16       Impact factor: 5.568

4.  Role of SFRS13A in low-density lipoprotein receptor splicing.

Authors:  I-Fang Ling; Steven Estus
Journal:  Hum Mutat       Date:  2010-06       Impact factor: 4.878

Review 5.  Insights on chiral, backbone modified peptide nucleic acids: Properties and biological activity.

Authors:  Maria Moccia; Mauro F A Adamo; Michele Saviano
Journal:  Artif DNA PNA XNA       Date:  2016-01-11

6.  Genetic variation and alternative splicing.

Authors:  Xavier Estivill
Journal:  Nat Biotechnol       Date:  2015-04       Impact factor: 54.908

Review 7.  Emerging mechanisms and consequences of calcium regulation of alternative splicing in neurons and endocrine cells.

Authors:  Aleh Razanau; Jiuyong Xie
Journal:  Cell Mol Life Sci       Date:  2013-06-26       Impact factor: 9.261

8.  Molecular diagnosis of neurofibromatosis type 1: 2 years experience.

Authors:  Siân Griffiths; Peter Thompson; Ian Frayling; Meena Upadhyaya
Journal:  Fam Cancer       Date:  2007       Impact factor: 2.375

9.  Puberty and plexiform neurofibroma tumor growth in patients with neurofibromatosis type I.

Authors:  Urania Dagalakis; Maya Lodish; Eva Dombi; Ninet Sinaii; Jessica Sabo; Andrea Baldwin; Seth M Steinberg; Constantine A Stratakis; Brigitte C Widemann
Journal:  J Pediatr       Date:  2013-12-08       Impact factor: 4.406

10.  Prediction and assessment of splicing alterations: implications for clinical testing.

Authors:  Amanda B Spurdle; Fergus J Couch; Frans B L Hogervorst; Paolo Radice; Olga M Sinilnikova
Journal:  Hum Mutat       Date:  2008-11       Impact factor: 4.878

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.